Ratings by Citizens (Reni Benjamin)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/5/2026 | Sana Biotechnology | SANA | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 3/3/2026 | Zymeworks | ZYME | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 2/24/2026 | Summit Therapeutics plc | SMMT | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 2/23/2026 | Bicara Therapeutics Inc | BCAX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 2/20/2026 | Bicara Therapeutics Inc | BCAX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 2/17/2026 | Immutep Limited | IMMP | New Coverage | Market Outperform (N/A) |
2.74 (2.76) |
0.73% | Details | |
| 2/4/2026 | Prelude Therapeutics | PRLD | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 1/30/2026 | Summit Therapeutics plc | SMMT | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 1/29/2026 | Bicara Therapeutics Inc | BCAX | New Coverage | Market Outperform (N/A) |
16.77 (18.47) |
10.14% | Details | |
| 1/20/2026 | Sutro Biopharma | STRO | Upgrade | Market Outperform (Market Perform) |
13.07 (25.29) |
93.5% | Details | |
| 1/13/2026 | Summit Therapeutics plc | SMMT | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 1/13/2026 | Bicycle Therapeutics | BCYC | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 1/9/2026 | Allogene | ALLO | Upgrade | Market Outperform (Market Perform) |
1.49 (2.30) |
54.36% | Details | |
| 1/7/2026 | Zymeworks | ZYME | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 1/7/2026 | Instil Bio Inc | TIL | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 1/7/2026 | BeOne Medicines | ONC | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 1/7/2026 | Compass Therapeutics | CMPX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 12/19/2025 | Werewolf Therapeutics Inc. | HOWL | Downgrade | Market Perform (Market Outperform) |
0.65 (0.63) |
-3.08% | Details | |
| 12/17/2025 | Inhibrx Biosciences | INBX | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 12/11/2025 | BeOne Medicines | ONC | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 12/8/2025 | Prelude Therapeutics | PRLD | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 12/3/2025 | Zymeworks | ZYME | New Coverage | Market Outperform (N/A) |
26.03 (24.08) |
-7.49% | Details | |
| 12/3/2025 | Compass Therapeutics | CMPX | New Coverage | Market Outperform (N/A) |
5.46 (5.51) |
0.92% | Details | |
| 11/19/2025 | Inhibrx Biosciences | INBX | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 11/19/2025 | Adicet Bio Inc. | ACET | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 11/18/2025 | Instil Bio Inc | TIL | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 11/18/2025 | Cue Biopharma | CUE | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 11/17/2025 | Sutro Biopharma | STRO | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 11/14/2025 | Prelude Therapeutics | PRLD | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 11/12/2025 | Werewolf Therapeutics Inc. | HOWL | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 11/7/2025 | BeOne Medicines | ONC | Maintain | Market Outperform (N/A) |
|
Details | ||
| 10/31/2025 | Bicycle Therapeutics | BCYC | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 10/20/2025 | Summit Therapeutics plc | SMMT | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 10/8/2025 | Adicet Bio Inc. | ACET | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 9/10/2025 | Summit Therapeutics plc | SMMT | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 9/9/2025 | Adicet Bio Inc. | ACET | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 9/9/2025 | BioAtla Inc. | BCAB | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 9/8/2025 | Summit Therapeutics plc | SMMT | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 8/22/2025 | Inhibrx Biosciences | INBX | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 8/21/2025 | Sana Biotechnology | SANA | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 8/21/2025 | Werewolf Therapeutics Inc. | HOWL | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 8/20/2025 | Allogene | ALLO | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 8/19/2025 | Summit Therapeutics plc | SMMT | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 8/15/2025 | Instil Bio Inc | TIL | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 8/15/2025 | Sutro Biopharma | STRO | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 8/13/2025 | Adicet Bio Inc. | ACET | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 8/13/2025 | BioAtla Inc. | BCAB | Downgrade | Market Perform (Market Outperform) |
0.36 (0.17) |
-52.78% | Details | |
| 8/12/2025 | Bicycle Therapeutics | BCYC | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 8/4/2025 | Allogene | ALLO | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 6/24/2025 | Sana Biotechnology | SANA | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 6/3/2025 | Blueprint Medicines | BPMC | Downgrade | Market Perform (Market Outperform) |
101.35 (129.46) |
27.74% | Details | |
| 6/2/2025 | Instil Bio Inc | TIL | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 6/2/2025 | Summit Therapeutics plc | SMMT | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 5/14/2025 | Allogene | ALLO | Downgrade | Market Perform (Market Outperform) |
1.17 (1.49) |
27.35% | Details | |
| 5/7/2025 | BioAtla Inc. | BCAB | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 5/2/2025 | Blueprint Medicines | BPMC | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 5/2/2025 | Bicycle Therapeutics | BCYC | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 4/29/2025 | Prelude Therapeutics | PRLD | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 4/28/2025 | Summit Therapeutics plc | SMMT | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 4/21/2025 | Werewolf Therapeutics Inc. | HOWL | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 4/21/2025 | Summit Therapeutics plc | SMMT | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 4/21/2025 | Prelude Therapeutics | PRLD | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 4/21/2025 | Cue Biopharma | CUE | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 4/21/2025 | Blueprint Medicines | BPMC | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 4/21/2025 | BioAtla Inc. | BCAB | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 4/21/2025 | Adicet Bio Inc. | ACET | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 4/15/2025 | Cue Biopharma | CUE | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 4/2/2025 | Cue Biopharma | CUE | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 3/31/2025 | Lava Therapeutics NV | LVTX | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 3/31/2025 | BioAtla Inc. | BCAB | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 3/18/2025 | Inhibrx Biosciences | INBX | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 3/18/2025 | Sana Biotechnology | SANA | Upgrade | Market Outperform (Market Perform) |
2.93 (3.15) |
7.51% | Details | |
| 3/14/2025 | Sutro Biopharma | STRO | Downgrade | Market Perform (Market Outperform) |
1.34 (13.07) |
875.37% | Details | |
| 3/14/2025 | Allogene | ALLO | Upgrade | Market Outperform (Market Perform) |
2.06 (2.30) |
11.65% | Details | |
| 3/12/2025 | Prelude Therapeutics | PRLD | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 3/3/2025 | Blueprint Medicines | BPMC | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 2/26/2025 | Bicycle Therapeutics | BCYC | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 2/18/2025 | Blueprint Medicines | BPMC | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 2/14/2025 | Blueprint Medicines | BPMC | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 1/14/2025 | Werewolf Therapeutics Inc. | HOWL | Maintain | Market Outperform (N/A) |
|
Details | ||
| 12/18/2024 | Bicycle Therapeutics | BCYC | Maintain | Market Outperform (N/A) |
|
Details | ||
| 12/11/2024 | Prelude Therapeutics | PRLD | Maintain | Market Outperform (N/A) |
|
Details | ||
| 12/11/2024 | Lava Therapeutics NV | LVTX | Downgrade | Market Perform (Market Outperform) |
1.91 (1.74) |
-8.9% | Details | |
| 11/5/2024 | Sana Biotechnology | SANA | Downgrade | Market Perform (Market Outperform) |
3.66 (2.93) |
-19.95% | Details | |
| 11/4/2024 | Instil Bio Inc | TIL | New Coverage | Market Perform (N/A) |
31.77 (8.87) |
-72.08% | Details | |
| 11/4/2024 | Summit Therapeutics plc | SMMT | New Coverage | Market Outperform (N/A) |
18.59 (15.11) |
-18.72% | Details | |
| 9/18/2024 | BeiGene, Ltd. | BGNE | New Coverage | Market Outperform (N/A) |
196.45 (184.71) |
-5.98% | Details | |
| 7/26/2024 | Cue Biopharma | CUE | Maintain | Market Outperform (N/A) |
|
Details | ||
| 7/23/2024 | Inhibrx Biosciences | INBX | New Coverage | Market Perform (N/A) |
12.88 (69.18) |
437.11% | Details | |
| 5/23/2024 | BioAtla Inc. | BCAB | Maintain | Market Outperform (N/A) |
|
Details | ||
| 4/30/2024 | Deciphera | DCPH | Maintain | Market Perform (Market Outperform) |
|
Details | ||
| 4/3/2024 | Werewolf Therapeutics Inc. | HOWL | New Coverage | Market Outperform (N/A) |
6.38 (0.65) |
-89.81% | Details | |
| 3/13/2024 | Prelude Therapeutics | PRLD | New Coverage | Market Outperform (N/A) |
4.09 (3.23) |
-21.03% | Details | |
| 3/1/2024 | Sana Biotechnology | SANA | Maintain | Market Outperform (N/A) |
|
Details | ||
| 1/23/2024 | Inhibrx Inc. | INBX | Downgrade | Market Perform (Market Outperform) |
33.76 (69.18) |
104.92% | Details | |
| 1/10/2024 | Ambrx Biopharma | AMAM | Downgrade | Market Perform (Market Outperform) |
27.47 (28.00) |
1.93% | Details | |
| 1/5/2024 | Allogene | ALLO | Downgrade | Market Perform (Market Outperform) |
3.33 (2.06) |
-38.14% | Details | |
| 12/20/2023 | Bicycle Therapeutics | BCYC | Maintain | Market Outperform (N/A) |
|
Details | ||
| 10/12/2023 | Sana Biotechnology | SANA | Maintain | Market Outperform (N/A) |
|
Details | ||
| 9/25/2023 | Ambrx Biopharma | AMAM | New Coverage | Market Outperform (N/A) |
11.84 (28.00) |
136.49% | Details | |
| 9/25/2023 | Sana Biotechnology | SANA | New Coverage | Market Outperform (N/A) |
3.96 (3.66) |
-7.58% | Details | |
| 8/23/2023 | Inhibrx Inc. | INBX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 8/4/2023 | Bicycle Therapeutics | BCYC | Maintain | Market Outperform (N/A) |
|
Details | ||
| 6/27/2023 | Adicet Bio Inc. | ACET | Downgrade | Market Perform (Market Outperform) |
4.73 (7.29) |
54.12% | Details | |
| 5/5/2023 | Allogene | ALLO | Maintain | Market Outperform (N/A) |
|
Details | ||
| 4/3/2023 | Sutro Biopharma | STRO | Maintain | Market Outperform (N/A) |
|
Details | ||
| 3/27/2023 | BioAtla Inc. | BCAB | Maintain | Market Outperform (N/A) |
|
Details | ||
| 3/14/2023 | Seagen | SGEN | Downgrade | Market Perform (Market Outperform) |
172.61 (228.74) |
32.52% | Details | |
| 3/8/2023 | Inhibrx Inc. | INBX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 3/2/2023 | Allogene | ALLO | Maintain | Market Outperform (N/A) |
|
Details | ||
| 2/17/2023 | Seagen | SGEN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 1/9/2023 | eFFECTOR Therapeutics, Inc. | EFTR | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/17/2022 | eFFECTOR Therapeutics, Inc. | EFTR | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 11/9/2022 | Bicycle Therapeutics | BCYC | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/4/2022 | Blueprint Medicines | BPMC | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/2/2022 | Seagen | SGEN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 9/15/2022 | Lava Therapeutics NV | LVTX | New Coverage | Market Outperform (N/A) |
2.46 (1.91) |
-22.36% | Details | |
| 9/15/2022 | BioAtla Inc. | BCAB | New Coverage | Market Outperform (N/A) |
8.27 (0.36) |
-95.65% | Details | |
| 8/11/2022 | eFFECTOR Therapeutics, Inc. | EFTR | Maintain | Market Outperform (N/A) |
|
Details | ||
| 8/8/2022 | Compugen | CGEN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 8/5/2022 | Deciphera | DCPH | Upgrade | Market Outperform (Market Perform) |
13.57 (25.59) |
88.58% | Details | |
| 7/8/2022 | Seagen | SGEN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 4/18/2022 | Seagen | SGEN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 3/23/2022 | Cue Biopharma | CUE | Maintain | Market Outperform (N/A) |
|
Details | ||
| 3/3/2022 | Bicycle Therapeutics | BCYC | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 3/2/2022 | Inhibrx Inc. | INBX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 2/25/2022 | Compugen | CGEN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 2/25/2022 | Allogene | ALLO | Maintain | Market Outperform (N/A) |
|
Details | ||
| 2/16/2022 | Seagen | SGEN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 1/25/2022 | eFFECTOR Therapeutics, Inc. | EFTR | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/5/2021 | Deciphera | DCPH | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/2/2021 | Inhibrx Inc. | INBX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 10/14/2021 | Bicycle Therapeutics | BCYC | Maintain | Market Outperform (N/A) |
|
Details | ||
| 9/21/2021 | Inhibrx Inc. | INBX | New Coverage | Market Outperform (N/A) |
37.02 (69.18) |
86.87% | Details | |
| 9/21/2021 | eFFECTOR Therapeutics, Inc. | EFTR | New Coverage | Market Outperform (N/A) |
19.30 (0.18) |
-99.07% | Details | |
| 8/24/2021 | Trillium Therapeutics | TRIL | Downgrade | Market Perform (Market Outperform) |
6.09 (19.86) |
226.11% | Details | |
| 5/19/2021 | Iovanace Biotherapeutics | IOVA | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 4/20/2021 | Bicycle Therapeutics | BCYC | New Coverage | Market Outperform (N/A) |
29.45 (5.19) |
-82.38% | Details | |
| 3/19/2021 | Sutro Biopharma | STRO | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 3/19/2021 | Idera Pharmaceuticals | IDRA | Downgrade | Market Perform (Market Outperform) |
5.13 (0.43) |
-91.62% | Details | |
| 2/24/2021 | Seagen | SGEN | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 12/18/2020 | Blueprint Medicines | BPMC | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/10/2020 | Sutro Biopharma | STRO | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/9/2020 | Iovanace Biotherapeutics | IOVA | Maintain | Market Outperform (N/A) |
|
Details | ||
| 10/27/2020 | Aceto Corp. | ACET | New Coverage | Market Outperform (N/A) |
12.49 (7.29) |
-41.63% | Details | |
| 10/13/2020 | Seagen | SGEN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 9/23/2020 | Blueprint Medicines | BPMC | Maintain | Market Outperform (N/A) |
|
Details | ||
| 9/22/2020 | Seattle Genetics | SGEN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 9/17/2020 | Spectrum Pharmaceuticals | SPPI | New Coverage | Market Outperform (N/A) |
4.14 (1.03) |
-75.12% | Details | |
| 9/9/2020 | Trillium Therapeutics | TRIL | Maintain | Market Outperform (N/A) |
|
Details | ||
| 6/24/2020 | CTI BioPharma | CTIC | New Coverage | Market Outperform (N/A) |
1.27 (9.09) |
615.75% | Details | |
| 6/24/2020 | Constellation Pharmaceuticals | CNST | New Coverage | Market Perform (N/A) |
31.79 (33.99) |
6.92% | Details | |
| 5/31/2020 | Allogene | ALLO | Maintain | Market Outperform (N/A) |
|
Details | ||
| 5/26/2020 | Trillium Therapeutics | TRIL | New Coverage | Market Outperform (N/A) |
6.39 (19.86) |
210.8% | Details | |
| 5/26/2020 | NextCure Inc. | NXTC | New Coverage | Market Outperform (N/A) |
33.10 (17.88) |
-45.98% | Details | |
| 5/26/2020 | Compugen | CGEN | New Coverage | Market Outperform (N/A) |
14.31 (2.08) |
-85.46% | Details | |
| 5/26/2020 | Seattle Genetics | SGEN | New Coverage | Market Outperform (N/A) |
155.77 (228.74) |
46.84% | Details | |
| 4/29/2020 | Blueprint Medicines | BPMC | Maintain | Market Outperform (N/A) |
|
Details | ||
| 3/6/2020 | Cue Biopharma | CUE | Maintain | Market Outperform (N/A) |
|
Details | ||
| 1/22/2020 | Cue Biopharma | CUE | New Coverage | Market Outperform (N/A) |
15.40 (0.30) |
-98.05% | Details | |
| 1/14/2020 | Incyte | INCY | Maintain | Market Outperform (N/A) |
|
Details | ||
| 1/3/2020 | Incyte | INCY | Maintain | Market Outperform (N/A) |
|
Details | ||
| 12/18/2019 | Iovanace Biotherapeutics | IOVA | New Coverage | Market Outperform (N/A) |
27.50 (26.97) |
-1.93% | Details | |
| 12/18/2019 | Allogene | ALLO | New Coverage | Market Outperform (N/A) |
27.04 (2.30) |
-91.49% | Details | |
| 12/17/2019 | Deciphera | DCPH | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/5/2019 | Deciphera | DCPH | Maintain | Market Outperform (N/A) |
|
Details | ||
| 10/22/2019 | Deciphera | DCPH | Market Outperform (N/A) |
34.23 (25.59) |
-25.24% | Details | ||
| 10/22/2019 | Blueprint Medicines | BPMC | Market Outperform (N/A) |
75.15 (101.35) |
34.86% | Details | ||
| 9/30/2019 | Incyte | INCY | Maintain | Market Outperform (N/A) |
|
Details | ||
| 9/5/2019 | Sutro Biopharma | STRO | New Coverage | Market Outperform (N/A) |
8.01 (1.34) |
-83.27% | Details | |
| 9/5/2019 | Kura Oncology | KURA | New Coverage | Market Outperform (N/A) |
15.24 (8.96) |
-41.21% | Details | |
| 9/5/2019 | Idera Pharmaceuticals | IDRA | New Coverage | Market Outperform (N/A) |
2.60 (0.43) |
-83.46% | Details | |
| 9/5/2019 | ERYTECH Pharma SA. | ERYP | New Coverage | Market Outperform (N/A) |
5.22 (5.48) |
4.98% | Details | |
| 9/5/2019 | Incyte | INCY | New Coverage | Market Outperform (N/A) |
80.06 (95.94) |
19.84% | Details |
